肿瘤坏死因子－α（TNF－α）对常见呼吸道病毒的抑制作用

用人重组肿瘤坏死因子－α（Ｔｕｍｏｒｎｅｃｒｏｓｉｓｆａｃｔｏｒ－α,ＴＮＦ－α）和人天然α干扰素（Ｉｎｔｅｒｆｅｒｏｎ－α－,ＩＦＮ－α）在人胚胎肺纤维母细胞（ＨＥＦ）和Ｈｅｐ－２细胞系上对常见呼吸道病毒所致细胞病变抑制进行比较观察。病毒包括不同型别的腺病毒５株,单疱病毒Ⅰ型（ＨＳＶ－Ｉ）１株,鼻病毒１株,仙台病毒１株,ＶＳＶ１株。结果提示ＴＮＦ－α和ＩＦＮ－α均具有广谱抗病毒活性。ＴＮＦ－α的抑毒作用能被ＴＮＦ－α申抗和ＩＦＮ－β单抗完全去除,被ＩＦＮ－α单抗部分去除ＴＮＦ－α的抗病毒效应。ＴＮＦ－－α中和试验的结果提示：ＴＮＦ抗病毒活性仍为ＩＦＮ－β诱生所介导。     

碳酸锂处理糖尿病中国地鼠疗效观察

本文报道小剂量碳酸锂对自发的遗传性糖尿病模型中国地鼠（ＮＩＤＤＭ）三个月处理疗效观察。采用胰岛素敏感性指数——空腹血浆胰岛素与血糖乘积的倒数,判断药物疗效。结果显示：碳酸锂使糖尿病鼠血糖降低,血胰岛素无变化,胰岛素敏感性增强。     

以淀粉珠为载体的亲和层析法分离纯化高温α淀粉酶

 以淀粉珠为载体的亲和层析法分离纯化高温α淀粉酶张学忠,宋伦,王群,吴晓霞,唐锌进（吉林大学酶工程国家重点实验室,长春１３００２３;南京师范大学生物系,南京２１００２４）金凤燮等人从酒曲中筛选出高产热稳定α淀粉酶的菌株,命名为Ｂａｃｉｌｌｕｓｓｐ－ＪＦ...     

人粒细胞集落刺激因子（hG－CSF）cDNA3′－UTR对其表达的影响

利用人粒细胞集落刺激因子（ｈＧ－ＣＳＦ）ｃＤＮＡ３′端非翻译区（３′－ＵＴＲ）中存在的ＤｒａⅠ酶切位点,通过部分酶切与完全酶切,删除３′－ＵＴＲ不同长度,构建了四种ｈＧ－ＣＳＦｃＤＮＡ瞬时重组表达质粒。转染ＣＯＳ－７细胞后,生物活性测定结果提示,ｈＧ－ＣＳＦｃＤＮＡ３′－ＵＴＲ对其表达起负调控作用,其关键性序列位于紧接终止密码子ＴＧＡ下游的６５ｂｐ范围内,３′－ＵＴＲ对ｈＧ－ＣＳＦｃＤＮＡ表达的影响与转录水平的差别有一定关系。     

无花果蛋白酶在阴离子交换树脂上的固定化

无花果蛋白酶通过８％戊二醛活化载体,共价结合到聚苯乙烯阴离子交换树脂ＧＭ２０１上,固定化作用在ｐＨ７．７,酶浓度０．８ｍｇ／ｇ树脂,４℃下进行６ｈ。得到的固定化酶表观Ｋ_ｍ值（酪蛋白,１．１１×１０~（－４）ｍｏｌ／Ｌ）小于溶液酶Ｋ_ｍ值（１．９６×１０~（－４）ｍｏｌ／Ｌ）;固定化酶活性在ｐＨ６～８保持稳定,溶液酶最适ｐＨ为７．２;固定化酶最适温度由溶液酶的５０～６０℃移至３７℃;固定化酶２５℃保持７ｄ,重复水解酪蛋白７次后,保留８３．３％活性。固定化酶对酪蛋白水解度达４７．５％,对大豆球蛋白达１１．６％。     

玉米根细胞中对钒酸盐敏感的H~＋－泵的研究

用奎吖咽（ｑｕｉｎａｃｒｉｎｅ）作荧光指标剂,测定玉米（ＺｅａｍａｙｓＬ．）根尖微粒体（ＭＩＣ）膜囊泡的Ｈ~＋－泵活性,结果表明１ｍｍｏｌ／ＬＮａＮ_３仅抑制该泵活性约８％,而０．８ｍｍｏｌ／Ｌ钒酸盐（Ｖａｎ）则可抑制其活性达８０％,说明ＭＩＣ制剂中Ｈ~＋－泵活性主要由质膜（ＰＭ）Ｈ~＋－ＡＴＰａｓｅ产生。此泵活性严格需要Ｍｇ~（２＋）,二价阳离子作用大小的顺序为Ｍｇ~（２＋）＞Ｍｎ~（２＋）＞Ｚｎ~（２＋）＞Ｃａ~（２＋）＝０;阴离子作用大小的１顺序为Ｂｒ~－＞Ｃｌ~－＞ＮＯ_３~－＞ＳＯ_４~（２－）,并初步证实当质膜同侧发生电子传递时,没有跨膜Ｈ~＋梯度（△μＨ~＋）生成。     

薄层扫描法测定绞股蓝中人参皂甙Rb_1

用高效薄层扫描法测定了绞股蓝中人参皂甙Ｒｂ_１的含量,并进行分离、纯化,再用酸解法水解,测得其结合糖为葡萄糖。     

Evidence that 5-HT2 antagonism elicits a 5-HT3-mediated increase in dopamine transmission

Amperozide, a novel atypical antipsychotic drug with few extrapyramidal side effects, is a strong serotonin₂ (5-HT₂) antagonist but has low affinity for dopamine receptors in vitro. The effect of amperozide on the dopaminergic synapse was studied with an in vivo microdialysis technique using anesthetized male Sprague-Dawley rats. Following implantation of dialysis probes into the striatum and nucleus accumbens (NuAc), amperozide was intravenously infused as six consecutive incremental doses (0.5, 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg) at intervals of 15 min. From the beginning of drug infusion, perfusates were collected in fractions every 30 min throughout a total period of 120 min. The samples were then immediately analyzed by high-performance liquid chromatography with electrochemical detection. Amperozide induced a dose-related elevation of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindolacetic acid (5-HIAA) levels in both areas.p-Chlorophenylalanine (pCPA) pretreatment abolished the production of 5-HIAA in both areas and attenuated the amperozide-induced rise of DOPAC but not of dopamine. After pretreatment with an intravenous 5-HT₃ antagonist, MDL 72222, the amperozide-induced changes in dopamine, DOPAC and 5-HIAA in both areas were lower than in the saline control group. Preliminary data showed that afterpCPA pretreatment, incremental concentrations of the 5-HT₃ agonist 1-(m-chlorophenyl)-biguanide perfused via the probe also produced significant elevation of dopamine and DOPAC levels in these two areas. Taken together, these results suggest that amperozide may directly block 5-HT₂ receptors in the striatum and NuAc, thereby enhancing 5-HT transmission. The enhanced 5-HT transmission may activate postsynpatic 5-HT₃ receptors located on the dopaminergic terminals, leading to changes in dopamine transmission in these two areas.     

[125I]CGP 42112 reveals a non-angiotensin II binding site in 1-methyl-4-phenylpyridine (MPP+)-induced brain injury

Summary 1. Intracerebral injection of the oxidative metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1-methyl-4-phenylpyridine (MPP⁺), into the substantia nigra of adult rats resulted in a lesion at the injection site.2. Using autoradiography, we localized specific [¹²⁵]CGP 42112 binding that was not recognized by angiostensin II or angiotensin II AT₁ or AT₂ receptorselective ligands.3. Our results suggest that [¹²⁵I]CGP 42112 may be binding to activated microglia that appear at the lesion site.